Medicis Pharmaceutical Corp. filed a suit against Ranbaxy Laboratories Ltd. India for allegedly trying to market a generic version of Medicis’ Solodyn, a extended release tablet of minocycline HCl.
Medicis alleges Ranbaxy infringed on one or more claims under Medicis’ U.S. Patent 5,908,838 when it submitted an abbreviated new drug application for a generic version of Solodyn to the U.S. Food and Drug Administration.
In its suit, Medicis is requesting a permanent injunction preventing Ranbaxy from infringing its patent by selling the generic version.
Last year, Ranbaxy entered in to agreement with Pfizer to settle the worldwide patent dispute involving cholesterol lowering drug Atorvastatin. LIPITOR, which generated $12.7 billion in sales in 2007. The agreement allowed Ranbaxy to introduce a generic version of the drug in November 2011, with 180 days of exclusivity in the U.S.
Ranbaxy Laboratories Ltd., India’s largest pharmaceutical company, settled a patent infringement lawsuit with AstraZeneca in April 2008. AstraZeneca had filed a patent infringement lawsuit against Ranbaxy for trying to market a generic version of AstraZeneca’s Esomeprazole magnesium capsules, Omeprazole tablets and Felodipine capsules in the United States. Ranbaxy will be allowed to exclusively sell its generic version of Nexium (generic name Esomeprazole magessium) under a license from AstraZeneca on May 27, 2014. During the 180-day period following that date, Ranbaxy will distribute the only generic Esomeprazole magnesium product in the U.S.
0 comments:
Post a Comment